Development and validation of a stability indicating UPLC method for determination of ticlopidine hydrochloride in its tablet formulation

Saudi Pharmaceutical Journal

Volumn 19, Issue 3, 2011, Pages 159-164

  Ram, Vijay ^a   Kher, Govind ^a   Dubal, Kapil ^a   Dodiya, Bhavesh ^a   Joshi, Hitendra ^a  

^a SAURASHTRA UNIVERSITY   (India)

Author keywords

Stability indicating assay; Tablet formulation; Ticlopidine hydrochloride; UPLC method

Indexed keywords

TICLOPIDINE;

ARTICLE; CORRELATION COEFFICIENT; DRUG DEGRADATION; DRUG STABILITY; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TABLET FORMULATION; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VALIDATION PROCESS;

EID: 79957957223     PISSN: 13190164     EISSN: 13190164     Source Type: Journal    
DOI: 10.1016/j.jsps.2011.03.005     Document Type: Article

References (10)

1. Bakshi M., Singh S. Development of validated stability-indicating assay methods-critical review. J. Pharm. Biomed. Anal. 2002, 28(6):1011.
2. Bakshi M., Singh S. ICH guidance in practice: establishment of inherent stability of secnidazole and development of a validated stability-indicating high-performance liquid chromatographic assay method. J. Pharm. Biomed. Anal. 2004, 24:1.
3. Bakshi M., Singh B., Singh A., Singh S. The ICH guidance in practice: stress degradation studies on ornidazole and development of a validated stability-indicating assay. J. Pharm. Biomed. Anal. 2001, 26(6):891.
4. Borges N.C., Mendes G.D., Borges A., Oliveira S.E., Barrientos-Astigarraga R.E., Nucci G.D. Ticlopidine quantification in human plasma by high-performance liquid chromatography coupled to electrospray tandem mass spectrometry. Application to bioequivalence study. J. Mass Spectrom. 2004, 39:1562-1569.
5. Braunwald E., Angiolillo D., Bates E., Berger P.B., Bhatt D., Cannon C.P., Furman M.I., Gurbel P., Michelson A.D., Peterson E., Wiviott S. Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes. Clin. Cardiol. 2008, 31:I2.
6. Iida O., Nanto S., Uematsu M., Morozumi T., Kitakaze M., Nagata S. Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions. J. Vasc. Surg. 2008, 13.
7. Markopoulou C.K., Koundourellis J.E., Orkoula M.G., Kontoyannis C.G. Quantitative nondestructive methods for the determination of ticlopidine in tablets using reflectance near-infrared and fourier transform raman spectroscopy. Appl. Spectrosc. 2008, 62:251-257.
8. Papathanasiou A.I., Goudevenos J.A., Mikhailidis D.P., Tselepis A.D. Acute and long-term antiplatelet therapy. Drugs Today (Barc.) 2008, 44:331-352.
9. Pecanac D., Van Houtte F., Hoogmartens J. A stability study of ticlopidine products from 18 countries. Drug Dev. Ind. Pharm. 2000, 26:391-401.
10. Rona K., Ary K., Gachalyi B., Klebovich I. Liquid-chromatographic method for the determination of ticlopidine in human plasma. J. Chromatogr. B: Biomed. Sci. Appl. 1997, 693:393-398.